Ultrasound contrast agents are highly echogenic microbubbles with many unique properties. Microbubbles can basically improve the sensitivity of conventional ultrasound imaging to the microcirculation. The resonance of microbubbles in response to an incident ultrasound pulse results in nonlinear harmonic emission that serves as the signature of microbubbles in microbubble-specific imaging. Inertial cavitation and destruction of microbubbles can produce a strong mechanical stress enhancing the permeability of the surrounding tissues, and can further increase the extravasation of drugs from the blood into the cytoplasm or interstitium. Stable cavitation by high-frequency ultrasound can also mildly increase tissue permeability without causing any damage even at a high acoustic pressure. Microbubbles can carry drugs, release them upon ultrasound-mediated microbubble destruction, and simultaneously enhance vascular permeability to increase drug deposition in tissues. Various targeting ligands can be conjugated to the surface of microbubbles to attain ligand-directed and site-specific accumulation for targeted imaging. In addition to current developments in microbubble technology, this review introduces our studies of the applications of microbubble-specific imaging, ultrasound-aided drug delivery, and targeted imaging. These applications are promising but may require further improvement for clinical use. (Chang Gung Med J 2012;35:125-39) 
U ltrasound imaging has been one of the most popular medical diagnostic techniques because of its superior safety, low cost, and easy accessibility compared with other imaging modalities such as computed tomography, positron emission tomography, and magnetic resonance imaging (MRI). Ultrasound imaging can provide real-time quantitative information on the morphology and perfusion of biological tissues for evaluation of a variety of diseases in cardiology, radiology, and oncology. (1) (2) (3) (4) (5) In recent years, much attention has focused on observation of the microcirculation in the different types of diseases or abnormalities in tissues. For example, the dependence of angiogenesis on tumor growth and progression has highlighted the importance of noninvasive visualization of the tumor microvasculature to determine treatment strategies and assess therapeutic efficacies. (6) (7) (8) (9) However, the sensitivity and specificity of ultrasound diagnoses are susceptible to low contrast differences between blood and tissue. Conventional ultrasound Doppler imaging only permits flow assessment of vessels larger than hundreds of micrometers, such as arterioles and venules. These limitations have recently been overcome by the development of ultrasound contrast agents (UCAs).
The first use of UCAs was reported in echocardiography by Gramiak and Shah in 1968 . (10) These UCAs were room air bubbles with no protective shell, so they disappeared within a few seconds after intravenous administration. Currently-used UCAs are more stable microbubbles composed of low-diffusivity gases such as nitrogen or perfluorocarbon stabilized by a coating of biodegradable material such as albumin, phospholipids, or polymers. (11) Phospholipids are commonly used since lipid-coated microbubbles are easier to fabricate and are much more echogenic than those made of other materials. (12) Microbubbles are highly echogenic in vivo because of a mismatch in acoustic impedances (i.e., the product of density and the speed of sound) between their gas cores and surrounding tissues. Once administered into a body cavity or the cardiovascular system, microbubbles are capable of increasing the intensity of backscattered ultrasound to up to 20-30 dB. (13) The contrast enhancement can clarify delineation of the borders of body cavities (e.g., the left ventricular cavity) and increase the Doppler signals from intracranial vessels. (14) (15) (16) The improved sensitivity of ultrasound to microcirculation assists in characterization of possible lesions in the liver and assessment of the vascular phenotype of a tumor. (17) (18) (19) Several researchers have also reported the successful use of microbubbles in preclinical diagnoses of cardiovascular and renal diseases. (20) (21) (22) (23) In addition to contrast enhancing ability, microbubbles possess unique properties that can be exploited to improve both diagnoses and therapies. Taking advantage of these properties could lead to emerging applications such as microbubble-specific detection and ultrasound-controlled targeted drug delivery. These applications are promising for further improvement in ultrasound imaging of the microcirculation and treatment in the imaged regions. In this article, we review current developments in microbubble technology and efforts by our laboratory to realize these emerging applications. ® is only available in the European Union. Detailed information on these agents is available in the Table. (11, (24) (25) (26) The microbubbles in these agents are larger than 1 µm with useful imaging durations of less than 10 min.
Commercial and homemade microbubbles
Our previous studies have demonstrated the fabrication of homemade microbubbles in the submicron scale, as shown in Fig. 1A . (27, 28) These microbubbles are composed of perfluoropropane gas and phospholipids prepared in phosphate buffered saline with mean sizes of about 200-700 nm, as shown in Fig. 1B , which are much smaller than those in commercial agents (refer to the Table for comparisons). The concentrations within 0.8-7 µm are about 1-5 x 10 10 bubbles/mL with less than 0.1% of the whole population larger than 10 µm. The small size distribution prevents the microbubbles from being entrapped in the pulmonary capillary bed, thereby permitting a long imaging duration of up to 20 min in vivo; the imaging duration of SonoVue ® is less than 6 min. (29, 30) Note that phospholipids are commonly used in the formulation and manufacturing of liposomes, a drug delivery system currently approved by the United States Food and Drug Administration (FDA). Perfluoropropane gas is chemically inert and does not generate toxicity during metastasis. Hence, homemade microbubbles are biologically safe and biocompatible, and do not cause a severe immune response in the the host. They can ultimately be cleaned through the immune and respiration systems. (31, 32) Nonlinear properties of microbubbles Unlike rigid particles, microbubbles are highly compressible, and are able to oscillate, i.e., repeatedly expand and contract in response to the pressure changes of an ultrasound pulse. The wall velocity is achieved in the order of tens to hundreds of meters per second, as demonstrated by high-speed photography. (33) When driven at acoustic pressures as low as tens of kilopascals, microbubbles perform linear oscillations, and the frequency of the backscattered ultrasound is equal to that of the transmitted ultrasound. When the acoustic pressure is raised to hundreds of kilopascals, the oscillations of individual microbubbles are not typically sinusoidal. This results in the generation of nonlinear harmonic ultrasound waves in multiples of the transmitted fundamental frequency (e.g., half the fundamental frequency [subharmonics], twofold the fundamental frequency [second harmonics], threefold the fundamental frequency [third harmonics], etc). (34) Since these harmonic waves normally differ from those reflected from tissues (except subharmonics), they are regarded as the signature of microbubbles. Their intensities are highest when the microbubbles are resonating with the transmitted ultrasound, where the changes in backscattering cross section are the most significant. The resonance of microbubbles is a size-dependent effect. (34) For example, the resonance frequencies of microbubbles that we fabricated were about 10-40 MHz and those of the aforementioned commercial product were about 2-10 MHz. (34) (35) (36) Note that in these cases, the microbubbles oscillate readily and coherently with the incident ultrasound pulses. This process is generally referred to as stable cavitation.
Further increasing the acoustic pressure may result in the oscillation of microbubbles and transmitted ultrasound waves to the point where they become incoherent. In this case, each microbubble expands and contracts unstably for a few cycles and ultimately collapses within a very short time. When this occurs in a free field, shock waves can be generated and give rise to microstreaming. When near a wall, the collapse of each microbubble becomes asymmetrical, creating a liquid jet striking the wall. (37, 38) Both phenomena are referred to as inertial cavitation. When exposed to ultrasound of appropriate frequency and sufficient pressure, microbubbles may immediately be fragmented into small pieces in the order of nanometers, and the encapsulated gas entirely dissolves in the surrounding medium. (39) This process is referred to as the destruction of the microbubbles, which may cause microstreaming or liquid jets at energy levels even higher than inertial cavitation. (40) Note that both inertial cavitation and microbubble destruction including stable cavitation can cause mechanical stress to tissues in vivo. (41) Many studies suggest the mechanical stress can alter the permeability of the blood vessel and cell membrane to increase drug extravasation, which is introduced in later sections.
Linear contrast-enhanced ultrasound (CEUS) imaging
The strategies for contrast imaging are currently based on either the linear or nonlinear properties of microbubbles. The linear scheme simply utilizes the echo enhancement of microbubbles. One example is from our pervious study of a colon cancer model in a BALB/c mouse. The imaging was conducted using a homemade ultrasound imaging system with a singleelement 25-MHz focused transducer. (42) After the administration of microbubbles, the contrast of tumor tissue was clearly enhanced for up to 6 min, as shown in Fig. 2A -F. Owing to the entrances and exits of circulating microbubbles to the imaging plane, the regional brightness varied over a period of time. These variations served as the signature of the microbubbles, and they were extracted using a highpass filter for interframe filtering. The obtained information was demonstrated as a color-coded overlay on a colocalized B-mode image, as shown in Fig.  2G , which clearly showed the distribution of the tumor microcirculation. The color pixel values were proportional to the microvascular blood flow volume and velocity. Further, a destruction-replenishment technique can be used to accurately assess the flow velocity of the microcirculation. In this technique, a destructive ultrasound pulse was first used to destroy most of the microbubbles in the region of interest. Blood flow velocity can be measured based on the refill rate of microbubbles indicated by the recovery of contrast enhancement. The concept of this technique was first described by Wei et al. in 1998 for use in echocardiology. (43) An adaptation has been made by our group to improve the sensitivity of this technique for use in microperfusion. (44, 45) Nonlinear CEUS imaging (microbubble-specific contrast imaging)
The performance of conventional CEUS imaging can deteriorate with low bubble concentration, tissue motion, and slow perfusion. Several studies have shown the utilization of microbubble nonlinear emissions in microbubble-specific contrast imaging. (46, 47) The second harmonics are not used because of interference from tissues at the same frequency. (48) However, inducing the resonance of microbubbles requires the application of sufficiently long ultrasound pulses. Since the resonance frequencies of commercial agents are 2-10 MHz, imaging at a half of these frequencies with long pulses can lead to low spatial resolution. To overcome this limitation, a phase inversion technique that utilizes the sum of a pair of images obtained from 2 inverted short ultrasound pulses was proposed. (49) The oscillation of microbubbles results in nonlinear distortion of reflected echoes that cannot be clearly cancelled in paired images, thereby leaving the signature of microbubbles in the summed image. Nonetheless, this technique has to be operated at half the maximum frame rate, and its performance may still be susceptible to movement. Our group has demonstrated two techniques to perform nonlinear contrast imaging with improved spatial resolution. One is amplitude modulation chirp imaging, which utilizes 2 different ultrasound pulses transmitted from separate ultrasound transducers. (50) A low-frequency pumping pulse is transmitted to induce resonance of the microbubbles. A high-frequency chirp pulse for imaging is then transmitted to simultaneously act on the same group of microbubbles. Periodic changes in the backscattering cross sections of the microbubbles in response to the pumping pulse can modulate the amplitude of the backscattered echoes of the chirp pulse, producing modulated components in the frequency spectrum, as shown in Fig. 3A-D . After extracting the derived signal components and applying pulse compression, the contrast of microbubbles can be differentiated from that of tissues in a high spatial resolution. The performance was evaluated by imaging a mouse tail vein, as shown in Fig. 3E . The other nonlinear imaging technique is a dual-frequency (DF) chirp imaging, which utilizes a unique ultrasound pulse that integrates DF difference excitation and chirp excitation techniques. (51) Our previous studies have shown that the DF difference excitation efficiently induces a low-frequency driving force to resonate microbubbles by using high-frequency ultrasound. (52, 53) High lateral resolution can be achieved by high-frequency carriers, and axial resolution can be improved after applying pulse compression. Our previous study also showed that DF difference excitation can improve the ability of high-frequency ultrasound to destroy microbubbles, which may be beneficial in the applications of commercial microbubbles in a high-frequency ultrasound system. (54, 55) In the future, we aim to incorporate these 2 imaging strategies into clinical ultrasound systems.
Therapeutic usefulness of microbubble cavitation
The therapeutic usefulness of microbubbles has gained much attention in recent years. Both inertial cavitation and destruction of microbubbles are capable of producing strong mechanical stress to enhance the permeability of the surrounding tissues and fur- ther increase the extravasation of drugs into the cytoplasm or interstitium, as illustrated in Fig. 4A . This may involve several mechanisms. High-energy microstreaming and liquid jets arising from the collapse of microbubbles can locally produce transient holes for direct passage of drugs. (41) They may also cause a transient increase in temperature (reportedly up to 5000 K) to alter the fluidity of the cell membrane. (56) Local deposition of such high energy may result in the production of free radicals, which probably cause cell damage that enhances the permeability of endothelial cell layers. (57) In vivo applications have focused, for instance, on disrupting the blood-brain barrier (BBB), a layer of tightly-packed endothelial cells surrounding all capillaries in the brain. (58) Many groups have reported the use of commercial microbubbles with low-frequency ultrasound (0.4-5 MHz) to increase the permeability of the BBB, allowing the therapeutic or diagnostic agents to leak into the affected regions. (59) (60) (61) The opening can be temporary and recoverable, and does not damage the neural cells. (62, 63) However, microbubbles exposed to low-frequency ultrasound have been shown to cause rupture of microvessels with extravasation of red blood cells, even at a pressure under the FDA regulatory limit for diagnostic ultrasound equipment. (64) The clinical safety of BBB disruption with low-frequency ultrasound still carries great concern about the risk of intracerebral hemorrhage. (65) Given that concern, our group has developed a high-frequency-based technique (> 10 MHz) to disrupt the BBB by using stable cavitation of microbubbles. It has been shown that stable cavitation may also mildly increase the tissue permeability by induced acoustic streaming. (41) A noteworthy advance that we have made in this technique was the use of homemade microbubbles that resonate at > 10 MHz. Sprague-Dawley rats were used in these experiments. The presence of BBB disruption was evaluated by the extravasation of a model drug, Evans blue, into the brain tissue; the results are demonstrated in Fig. 4B-D . Stable cavitation at a high frequency enhanced by the resonance of small microbubbles was able to produce effective BBB disruption, which was comparable to that with the low-frequency technique but without any damage even at pressures of up to 2.5 MPa. Interestingly, the amount of drug extravasation was found to highly correlate with the enhancement of subharmonic emission (i.e., the signature of stable cavitation of microbubbles), as shown in real time suggests this technique has great promise in clinical use.
Drug-loaded microbubbles and ultrasound-controlled release
Microbubbles have been proposed as a new vehicle for carrying drugs and genes. Lipophilic chemotherapeutic drugs such as doxorubicin, paclitaxel, and docetaxel can be incorporated into the lipid layer of microbubbles. (66) (67) (68) It has been shown that the in vivo toxicity of paclitaxel-loaded microbubbles is about tenfold lower than that of unencapsulated paclitaxel. (69) To increase the loading capacity, oil that dissolves lipophilic drugs can be introduced into the microbubbles. (70) (71) (72) Drug-loaded particles such as micelles or liposomes can be conjugated to the surface of microbubbles using ligand-receptor interaction. (73) Genetic materials (e.g., plasmid DNA) can be electrostatically attached to the surface of positively charged microbubbles that bear cationic lipids. (74) Unlike liposomes, drugloaded microbubbles are acoustically active and are able to exhibit stable or inertial cavitation in response to ultrasound. The payload of drugs or DNA can be locally released by the destruction of microbubbles within the ultrasound-treated region, with a simultaneous increase in the permeability of the tissues. This suggests the potential of microbubble technology in aiding drug or gene therapy, with reduced side effects to normal tissues.
Our group has developed the loading of microbubbles with 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU), a chemotherapeutic agent commonly used in the treatment of brain tumors. (75) The loading efficiency achieved was 75%, as shown in Fig. 5A . Sprague-Dawley rats were used to test the delivery of BCNU by these microbubbles into brain tissues. The deposition of BCNU in the left hemispheres treated by ultrasound increased with the number of sonication sites, and was higher than that in the right hemispheres which had no ultrasound treatment, as shown in Fig. 5B . This indicates that the destruction of BCNU-loaded microbubbles released the BCNU payload and simultaneously induced the disruption of the BBB for passage of BCNU into the brain tissues. The therapeutic effica- cy of delivered BCNU was further validated on a rat brain glioma model. The results of MRI monitoring show that the tumor volume on day 13 had reduced to 37% of its original volume on day 6, as shown in Fig. 5C .
Ultrasound targeted contrast agents and imaging
Over the past decade, the development of biomolecular science has extended traditional morphology and perfusion imaging to functional imaging in the assessment of the presence and extent of diseases at a molecular scale. Ultrasound targeted imaging relies on microbubble contrast agents conjugated with targeting ligands that specifically bind to the molecular signatures of diseases or physiological systems. Various ligands, typically antibodies and peptides, have been conjugated to the surface of microbubbles. (76) Site-specific accumulation of image contrast from targeted microbubbles provides great opportunities to noninvasively visualize physiology or pathology that is difficult to distinguish simply based on conventional morphological information. Preclinical applications have been reported in the assessment of atherosclerosis by the expression of intercellular adhesion molecule-1, and vascular thrombi by the expression of glycoprotein IIb/IIIa receptors. (77, 78) The extent of tissue inflammation can also be evaluated after incorporating phosphatidylserine lipids into microbubbles to attach to leukocytes. (79) Note that the conjugation can be conducted by either noncovalent linkage, such as biotin-avidin interaction, or covalent linkage, such as maleimide-thiol tethering. Although the biotin-avidin interaction has been extensively used in preclinical studies, the covalent linkage is generally preferable in clinical settings because it is more stable and has lower immunogenicity. (76) Our group demonstrated a simple way to conjugate a new class of targeting ligand, aptamers, to the surface of microbubbles via maleimide-thiol conjugation, as illustrated in Fig. 6A . (28) Aptamers are RNA-or DNA-based targeting ligands fabricated by a process of systematic evolution of ligands by expo- 63% Volume reduction nential enrichment. (80) They are biologically stable, less immunogenic, and have low manufacturing costs, but have comparable or even greater binding affinity and specificity than protein-based antibodies. The methods that we proposed are capable of completing the conjugation prior to the formation of microbubbles. Fewer steps will be required in clinical settings. The sgc8c aptamer (50-thiol-ATC TAA CTG CTG CGC CGC CGG GAA AAT ACT GTA CGG TTA GA) was used for the specific targeting of CCRF-CEM cells (CCL-119 T-cell, human acute lymphoblastic leukemia). A flexible polyethylene glycol spacer was designed between each aptamer and the surface of the microbubble to maximize interaction between each aptamer and receptors. The in vitro results show that the aptamer-conjugated microbubbles firmly bound to the surface of the CEM cells, and provided a great echo enhancement of up to 40 dB in the ultrasound image in comparison with the control, as shown in Fig. 6B-E .
In another in vivo study, we conjugated vascular endothelial growth factor receptor 2 (VEGFR2) antibodies onto microbubbles to assess tumor angiogenesis. After administration into a mouse with a colon tumor, the microbubbles gradually accumulated in the tumor site during the wash-in and wash-out phases of circulating microbubbles, as illustrated in Fig.  7A . After the clearance of the circulating microbubbles, the remaining contrast enhancement could mostly be attributed to the adherent microbubbles. The extent of tumor angiogenesis correlating to the expression of VEGFR2 was visualized by subtracting the images before and after microbubble accumulation, as shown in Fig. 7B . For comparison, no accumulation was found for normal microbubbles in the control test, as shown in Fig. 7C . The immunostained section of the tumor for DAPI (blue) and CD31 (red) in Fig. 7D and E, respectively, proved that the accumulation of microbubbles (green) was near the tumor boundary where angiogenesis was significant.
Challenges and limitations
As described earlier, microbubbles are able to carry drugs or genes, and locally release the payload by applying ultrasound in the intended regions. The targeting ability of bioconjugated microbubbles opens the door for targeted therapy. Combined with the aforementioned microbubble technology, microbubbles can serve as a multifunction platform that is not only useful in diagnoses but also in therapies, permitting simultaneous imaging and localiza- tion of the therapy. However, there are still some challenges in targeted and drug-loaded microbubbles that must be overcome before they are approved for clinical use. The adhesion efficiency of targeted microbubbles might be low under certain physiological flow conditions. (81) Although the microbubbles fabricated in our studies can exist in vivo for up to 20 min, some situations may require them to remain in vivo for several hours or more than one day to attain an accumulated contrast or therapeutic effect. The challenges may be overcome by acoustic radiation force, which has been demonstrated to accelerate the adhesion and accumulation of targeted microbubbles. (82) The mechanism is to drive these microbubbles toward the vessel wall by using lowenergy ultrasound without causing microbubble disruption. Another method is the use of polymershelled microbubbles, which are acoustically active in vivo for several hours. (83) Our group is currently developing the precursors of microbubbles-phase-change droplets-as ultrasound contrast agents. These droplets are originally in the liquid phase but can be vaporized into gaseous microbubbles upon ultrasound excitation. (84) Droplets are much more stable in vivo for more than 1 day, and carry a larger drug payload than conventional microbubbles. (85) Nanoscale agents are much easier to fabricate in the liquid phase than in the gaseous phase. The small size might allow the droplets to extravasate from the blood vessel to interact with receptors that may be present within tissues, and may enable passive targeting in tumors via an enhanced permeability and retention effect. (86) Research is underway to study whether the microbubbles derived from phase-change droplets can also be applied in the aforementioned microbubble technology.
Conclusions
In this article, we reviewed current developments in microbubble technology, and efforts by our laboratory in emerging diagnostic and therapeutic applications of microbubbles. Microbubbles were originally designed as UCAs to improve the sensitivity of conventional ultrasound imaging. The uniqueness of microbubbles, including bioconjugation, drug encapsulation, cavitation, and nonlinear emission, allow them to be used simultaneously as diagnostic and therapeutic agents. Applications include microbubble-specific imaging, ultrasound-aided drug delivery, and targeted imaging and therapy. Our group has developed two techniques of microbubblespecific imaging with high spatial resolution. Our group has also developed lipid-based microbubbles with a drug payload (e.g., BCNU) and targeting ligands (e.g., VEGFR2 antibodies). In vivo studies showed the visualization of tumor angiogenesis in a mouse colon tumor by VEGFR2-targeted microbubbles, and the therapeutic effect of ultrasound-aided BCNU delivery to a rat brain tumor. Stable cavitation at high frequency enhanced by the resonance of small microbubbles seems to be a very safe modality for enhancing tissue permeability. These applications are promising but require further improvement for clinical use.
